{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:39:18Z","timestamp":1778132358023,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A case of diffuse alveolar hemorrhage (DAH) occurring as a reaction to ustekinumab therapy is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>After starting ustekinumab for treatment of psoriatric arthritis, a 46-year-old female presented with flu-like symptoms and cough with blood-tinged sputum that had begun 1 week previously. Her initial computed tomography scan of the chest demonstrated bilateral ground-glass opacities. On bronchoscopy, the bronchoalveolar lavage (BAL) return became bloodier from sample 1 to samples 2 and 3. Her BAL fluid was more than 90% hemosiderin-laden macrophages, a finding consistent with DAH. We ruled out infectious etiologies and other common vasculitis conditions that can cause DAH. A diagnosis of ustekinumab-induced DAH was made due to a temporal relationship between initiation of the drug and the patient\u2019s presentation and the absence of infection and other alternate diagnosis. Prior case reports including ustekinumab-induced pneumonitis, interstitial lung disease with a granulomatous component, and lupus syndrome have been reported, with this being the first case of DAH in a patient undergoing treatment of psoriatic arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A 46-year-old woman developed DAH during ustekinumab treatment. Symptoms abated after drug discontinuation and supportive treament. Clinicians must remain mindful of this rare complication of ustekinumab use in order to avoid potential delays in appropriate DAH treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab156","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T16:48:41Z","timestamp":1617727721000},"page":"1277-1281","source":"Crossref","is-referenced-by-count":6,"title":["Diffuse alveolar hemorrhage associated with ustekinumab treatment"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-1630","authenticated-orcid":false,"given":"Kulothungan","family":"Gunasekaran","sequence":"first","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care, Yale-New Haven Health Bridgeport Hospital, Bridgeport, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department on Internal Medicine, Yale-New Haven Health Bridgeport Hospital, Bridgeport, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageshwari","family":"Palanisamy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep","family":"Singh Rahi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care, Yale-New Haven Health Bridgeport Hospital, Bridgeport, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand","family":"Wolff","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care, Yale-New Haven Health Bridgeport Hospital, Bridgeport, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,4]]},"reference":[{"issue":"5","key":"2021071005385657100_CIT0001","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/imt-2017-0149","article-title":"A review of ustekinumab in the treatment of psoriatic arthritis","volume":"10","author":"Roberts","year":"2018","journal-title":"Immunotherapy."},{"issue":"10","key":"2021071005385657100_CIT0002","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/2040622318781760","article-title":"Ustekinumab in psoriatic arthritis and related phenotypes","volume":"9","author":"Dobbin-Sears","year":"2018","journal-title":"Ther Adv Chronic Dis."},{"issue":"13","key":"2021071005385657100_CIT0003","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"2021071005385657100_CIT0004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jamadermatol.2018.4118","article-title":"Association of noninfectious pneumonia with ustekinumab use","volume":"155","author":"Brinker","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"3","key":"2021071005385657100_CIT0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annder.2014.11.004","article-title":"[Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis]","volume":"142","author":"Amy de la Bret\u00e8que","year":"2015","journal-title":"Ann Dermatol Venereol."},{"issue":"3","key":"2021071005385657100_CIT0006","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1684\/ejd.2013.2006","article-title":"Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment","volume":"23","author":"Yashiro","year":"2013","journal-title":"Eur J Dermatol."},{"issue":"5","key":"2021071005385657100_CIT0007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5152\/TJAR.2017.31967","article-title":"Stop being so sensitive: an exceptionally rare report of ustekinumab-induced sub-acute hypersensitivity pneumonitis","volume":"45","author":"Ali","year":"2017","journal-title":"Turk J Anaesthesiol Reanim."},{"issue":"1","key":"2021071005385657100_CIT0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13256-019-2137-1","article-title":"Sarcoid-like phenomenon \u2014 ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature","volume":"13","author":"Gad","year":"2019","journal-title":"J Med Case Rep."},{"issue":"2","key":"2021071005385657100_CIT0009","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","article-title":"A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial","volume":"168","author":"Tsai","year":"2013","journal-title":"Br J Dermatol."},{"issue":"4","key":"2021071005385657100_CIT0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1684\/ejd.2014.2386","article-title":"Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis","volume":"24","author":"Errichetti","year":"2014","journal-title":"Eur J Dermatol."},{"issue":"4","key":"2021071005385657100_CIT0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2146\/ajhp160010","article-title":"Pneumonia possibly due to ustekinumab therapy in a patient with Crohn\u2019s disease","volume":"74","author":"Borr\u00e1s-Blasco","year":"2017","journal-title":"Am J Health-Syst Pharm."},{"issue":"4","key":"2021071005385657100_CIT0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00105-019-04519-9","article-title":"[Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab]","volume":"71","author":"Sorger","year":"2020","journal-title":"Hautarzt."},{"issue":"3","key":"2021071005385657100_CIT0013","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2340\/00015555-3084","article-title":"A case of interstitial lung disease and autoimmune thyroiditis associated with ustekinumab","volume":"99","author":"Lee","year":"2019","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"2021071005385657100_CIT0014","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/1346-8138.13250","article-title":"Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment","volume":"43","author":"Kikuchi","year":"2016","journal-title":"J Dermatol."},{"issue":"12","key":"2021071005385657100_CIT0015","first-page":"1505","article-title":"Mycobacterium abscessus infection during ustekinumab treatment in crohn\u2019s disease: a case report and review of the literature","volume":"12","author":"Shim","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2021071005385657100_CIT0016","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bcp.12837","article-title":"Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus","volume":"81","author":"Guarneri","year":"2016","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"2021071005385657100_CIT0017","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jdcr.2019.01.015","article-title":"Ustekinumab-induced subacute cutaneous lupus","volume":"5","author":"Tierney","year":"2019","journal-title":"JAAD Case Rep."},{"issue":"12","key":"2021071005385657100_CIT0018","first-page":"889","article-title":"Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF\u03b1 agents","volume":"10","author":"Dalle Vedove","year":"2012","journal-title":"J Dtsch Dermatol Ges."},{"issue":"1","key":"2021071005385657100_CIT0019","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40360-018-0267-5","article-title":"Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report","volume":"19","author":"Myro","year":"2018","journal-title":"BMC Pharmacol Toxicol."},{"issue":"1","key":"2021071005385657100_CIT0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.transproceed.2014.10.037","article-title":"Diffuse alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation","volume":"47","author":"Tahir","year":"2015","journal-title":"Transplant Proc."},{"issue":"6","key":"2021071005385657100_CIT0021","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1378\/chest.07-2354","article-title":"Diffuse alveolar hemorrhage following alemtuzumab","volume":"133","author":"Sachdeva","year":"2008","journal-title":"Chest."},{"issue":"5","key":"2021071005385657100_CIT0022","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/hyu023","article-title":"Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case","volume":"44","author":"Ikeda","year":"2014","journal-title":"Jpn J Clin Oncol."},{"key":"2021071005385657100_CIT0023","first-page":"bcr0820103224","article-title":"Diffuse alveolar haemorrhage may be associated with intravitreal injection of bevacizumab in a patient with systemic risk factors","author":"Seto","year":"2011","journal-title":"BMJ Case Rep."},{"issue":"8","key":"2021071005385657100_CIT0024","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704886","article-title":"Diffuse alveolar hemorrhage following gemtuzumab ozogamicin","volume":"35","author":"Lin","year":"2005","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"2021071005385657100_CIT0025","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/1759-7714.12872","article-title":"Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma","volume":"9","author":"Ikeda","year":"2018","journal-title":"Thorac Cancer."},{"issue":"3","key":"2021071005385657100_CIT0026","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00054725-200405000-00016","article-title":"Diffuse alveolar hemorrhage after infliximab treatment of Crohn\u2019s disease","volume":"10","author":"Panagi","year":"2004","journal-title":"Inflamm Bowel Dis."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab156\/36875208\/zxab156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/14\/1277\/38891798\/zxab156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/14\/1277\/38891798\/zxab156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T08:40:13Z","timestamp":1625906413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/14\/1277\/6210057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,4]]},"references-count":26,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,4,4]]},"published-print":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab156","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,15]]},"published":{"date-parts":[[2021,4,4]]}}}